{"id":"W2913215587","doi":"10.3389/fimmu.2019.00040","title":"Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies","year":2019,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"Immunodeficiency and Autoimmune Disorders","field":"Immunology and Microbiology","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"University of California, Irvine; University of Alberta","keywords":"Tolerability; Medicine; Adverse effect; Prospective cohort study; Antibody; Internal medicine; Pediatrics; Anesthesia; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008999033,0.0002271696,0.0005613313,0.0001302157,0.0001208702,0.0003612998,0.0001630766,0.0002878661,0.0009666295],"category_scores_gemma":[0.0007946535,0.0001039277,0.0003740378,0.0001351493,0.0002011836,0.0002201993,0.0001495104,0.0005597373,0.0001314127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002457928,"about_ca_system_score_gemma":0.0002960138,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002424708,"about_ca_topic_score_gemma":0.00044125,"domain_scores_codex":[0.9997064,0.0001360128,0.00003047586,0.00003800309,0.00006513207,0.00002379293],"domain_scores_gemma":[0.9994448,0.0001568265,0.0002245187,0.00001764801,0.00004158112,0.0001146442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2497469,0.01381276,0.1637305,0.002224195,0.001304821,0.0008825912,0.000525203,0.001804242,0.07132398,0.0001476415,0.002617393,0.4918797],"study_design_scores_gemma":[0.0528526,0.5472285,0.3758202,0.0002915259,0.0008346787,0.00297726,0.0002068795,0.001821988,0.01201561,0.00009556018,0.005814584,0.00004077537],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946104,0.004403097,0.00009749998,0.00008277644,0.00001396386,0.00009554079,0.00009951586,0.00001248558,0.000584612],"genre_scores_gemma":[0.9982359,0.0009663259,0.0002290257,0.0001171824,0.00003360329,0.0000575828,0.0002009761,0.000001640362,0.0001577666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009666295,"threshold_uncertainty_score":0.004759133,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.006349287908015364,"score_gpt":0.220113540752536,"score_spread":0.2137642528445206,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}